Omnicell, Inc.
’s
OMCL
focus on innovation and efforts to expand into new markets seem strategic. However, a tough competitive landscape is a dampener. Currently, Omnicell carries a Zacks Rank #2 (Buy).
Over the past year, Omnicell’s shares have outperformed the
industry
it belongs to. The stock has rallied 112.6% against the industry’s 13.9% decline.
Omnicell exited the second quarter of 2021 with better-than-expected revenues and earnings. The top line rose year over year on growth across both the operating segments. Second-quarter revenues were up 37% year over year and also exceeded the company’s guidance. The sequential revenue improvement reflected continued momentum in the commercial business and strong customer implementations. The year-over-year increase was partially attributable to the lower-than-typical year-ago quarter revenue levels due to the COVID-19 pandemic.
The company recently announced its intent to acquire FDS Amplicare in an effort to strengthen its Advanced Services portfolio, which continues to gain momentum in the market. The raised adjusted EPS guidance for 2021 also buoys optimism.
The company has also accelerated a shift to cloud-based solutions and tech-enabled services through the launches of Omnicell One and Central Pharmacy Dispensing Services. In 2021, the company has seen rapid growth in SaaS, subscription software and tech-enabled services bookings. In line with this, EnlivenHealth, a division of Omnicell recently launched personalized interactive voice response, a SaaS technology solution that automates patient communications and frees up pharmacists to spend more quality time with patients. The company currently forecasts 50% CAGR in advanced services from 2020 through 2025.
Omnicell is on track to achieve its 2025 targets driven by a number of factors, including improved business mix, benefits from long-term exclusive customer partnerships, economies of scale, manufacturing savings and process efficiencies.
On the flip side, the coronavirus pandemic has impacted the company’s results with slowdown in product bookings. Further, escalating costs and expenses are putting pressure on the company’s bottom line. In the second quarter, cost of product revenues increased 16.8% while cost of services and other revenues rose 18.3%. Selling, general, and administrative expense too escalated 28.5% year over year.
Key Picks
A few other top-ranked stocks from the broader medical space are
Envista Holdings Corporation
NVST
,
BellRing Brands, Inc.
BRBR
and
Bio-Rad Laboratories, Inc.
BIO
, each carrying a Zacks Rank #2. You can see
the complete list of Zacks #1 Rank (Strong Buy) stocks here
.
Envista Holdings has an estimated long-term earnings growth rate of 27%.
BellRing Brands has an estimated long-term earnings growth rate of 29%.
Bio-Rad has a projected long-term earnings growth rate of 35%.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
